Compositions and methods of treating retinal disease
Compositions and methods for treating macular degeneration and other forms of retinal disease whose etiology involves the accumulation of A2E and/or lipofuscin, and, more specifically, for preventing the formation and/or accumulation of A2E are disclosed
1. A compound selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
2. The compound of claim 1 which is:
or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 which is:
or a pharmaceutically acceptable salt thereof.
4. The compound of claim 1 which is:
or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a compound selected from the group consisting of:
and a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
6. The pharmaceutical composition of claim 5 , wherein the compound is:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
7. The pharmaceutical composition of claim 5 , wherein the compound is:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 5 , wherein the compound is:
or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.